ICLE 2022 | Accelerating the identification of clinically relevant T cell therapies

Elvira D’Ippolito, PhD, Technical University of Munich, Munich, Germany, describes her ongoing research into T cell responses to accelerate the identification of novel, clinically-relevant T cell therapies. She describes the development of functional screening methods based on T cell receptor (TCR) avidity to both identify TCR sequences that can recognize antigens of interest and predict TCR functionality. Dr D’Ippolito is also working on developing approaches to accelerate screening of TCRs to quickly identify lead candidates for clinical application, as well as the optimization of protocols for T cell engineering using non-viral CRISPR-cas9 technology. This interview took place at the International Conference on Lymphocyte Engineering (ICLE) 2022.